Iksuda Therapeutics

Iksuda Therapeutics Focuses on Developing Next-Generation Antibody-Drug Conjugates (ADCs) for Hard-to-Treat Hematological and Solid Tumors. The company's biotherapeutics are antibody-based therapies that help treat cancer and other tumor-related diseases, enabling doctors to improve patients' lives.